Zepbound and Mounjaro sales soar
Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs saw significant sales growth during the second quarter, surpassing Wall Street estimates and widening the gap with Danish rival Novo Nordisk.
Intelligence analysis by Llama
Zepbound and Mounjaro sales soared in the second quarter, beating Wall Street estimates and solidifying Eli Lilly's position in the obesity market. The company's strong results are likely to reassure investors about demand for its GLP-1 treatments.
Imagine you have a special medicine that helps you lose weight and control your blood sugar levels. Eli Lilly makes this medicine, and people are buying it a lot. This is good news for the company, as it means they are selling more medicine than expected. The medicine is called Zepbound and Mounjaro, and it's helping people all around the world.
Analysis
A $60B Vote of Confidence
Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs have seen significant sales growth during the second quarter, surpassing Wall Street estimates and widening the gap with Danish rival Novo Nordisk. The strong results are likely to reassure investors about demand for Lilly's GLP-1 treatments, which remain resilient despite pricing pressure and intensifying competition from Novo. The company's sales of Mounjaro rose 91% to $9.94 billion, beating analysts' estimates, while Zepbound brought in $4.93 billion, compared with expectations of $4.73 billion. The two drugs accounted for 64.7% of Lilly's revenue in the quarter.
Why Cursor?
Many pharmaceutical industry experts had expected patients to prefer pills over injections for convenience. However, the trend was evident in the U.S. government's Medicare obesity drug pilot launched last month, where about 80% of patients chose to begin treatment with an injectable medicine. This suggests that patients are still opting for injectable GLP-1 medicines, even as oral obesity pill options have come into the market. The market continues to underappreciate the strength of Mounjaro demand outside the U.S. and its longer-term international growth potential.
The Road Ahead
Lilly and Novo dominate the lucrative obesity market, with the global market for obesity drugs reaching $66 billion in 2025, according to data firm IQVIA. Analysts expect it to hit over $100 billion annually by 2030 in the U.S. alone. Citi analysts said the outlook for the remainder of the year would depend on volume growth, driven by expanded Medicare access and sustained international demand for Mounjaro. Lilly now expects revenue of $85 billion to $87 billion for 2026, up from its previous forecast of $82 billion to $85 billion.
Key points
- Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs saw significant sales growth during the second quarter.
- The strong results are likely to reassure investors about demand for Lilly's GLP-1 treatments.
- The company's sales of Mounjaro rose 91% to $9.94 billion, beating analysts' estimates.
- Zepbound brought in $4.93 billion, compared with expectations of $4.73 billion.
- The two drugs accounted for 64.7% of Lilly's revenue in the quarter.
If this trend continues, Eli Lilly's Zepbound and Mounjaro sales could reach new heights, solidifying the company's position in the obesity market. The strong demand for injectable GLP-1 medicines suggests that patients are still opting for these treatments, despite the availability of oral obesity pill options.
However, the market is highly competitive, and Eli Lilly faces intense competition from Danish rival Novo Nordisk. If Novo's oral Wegovy pill continues to gain traction, it could potentially erode Lilly's market share and impact the company's sales growth.
